Belite Bio (BLTE) announced the completion of enrollment of 60 subjects, including 15 Japanese subjects, in the Phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt disease type 1. DRAGON II clinical trial is a global, 24-month, randomized, double-masked, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of tinlarebant in adolescent patients with STGD1. The trial had a targeted enrollment of 60 adolescent subjects aged 12 to 20 years old across Japan, the United States, and the United Kingdom, with participants randomized 1:1 to receive either tinlarebant or placebo.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Netflix, Meta upgraded: Wall Street’s top analyst calls
- Belite Bio initiated with a Buy at BofA
- Belite Bio initiated with an Overweight at Morgan Stanley
- Belite Bio: Tinlarebant’s First-Mover Advantage in STGD1 Supports Multi‑Billion Revenue Outlook and Further Upside Potential
- Belite Bio participates in a conference call with H.C. Wainwright